Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

NCT05093374

Status	RECRUITING
Phase	Phase 4
Sponsor	Medical University of Vienna
Enrollment	290 participants

Key Eligibility Criteria

Inclusion (6)

- Adults e 50 years
- Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA
- Patients who have a BCVA score better or equal 0.1 (20/200) in the study eye using ETDRS
- No significant fibrosis or geographic atrophy (GA) involving the fovea
- Willingness and ability to comply with study visits and study procedures

... and 1 more (see full listing online)

Exclusion (15)

- Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)
- Any surgical treatment of the eye within 3 months prior to baseline in the study eye
- History of pseudophakic cystoid macular edema (Irvine Gass Syndrome)
- History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.)
- History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) e 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio \>0,9

... and 10 more (see full listing online)

Locations (1 total)

Department of Ophthalmology, Medical University of Vienna, Austria, Vienna, Vienna, Austria